Without a hope, page-201

BIT are just not sophisticated enough to be a successful company let alone retain its market cap at $50m while...

Accumulated losses continue to rise

Cash on Hand continues to decline setting up for another equity raising diluting existing shareholders invested capital value ($ per share)

Expenses, salaries, and 'performance' bonuses (what a joke) continue to rise

Management and BIT fail at releasing price sensitive information to the market (ie poor assay results)

What a sad state of affairs

See Clip Below
@3.28min
Back in March 2013! MM said BIT225 would have FDA Approval and that their target for the drug to be in the market would be 3 - 5 years (ie 2016) - what an an epic failure and error of judgement that has been

Since 20 years of development....NOTHING. No FDA Approval! No Partnership, No License Agreement, No Commercial Deal and HepC has been a complete failure

MM throw in the towel already...the common denominator of failure is you